 Oramed Pharmaceuticals Inc. Nasdaq: ORMP TASE: ORMP a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the companys End of Phase 2 EOP2 meeting for Orameds oral insulin ORMD-0801. Based on the FDAs feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application BLA that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. 